Edesa Biotech is trading at $4.28, down 10.03%, after pricing a $25 million underwritten public offering.
- Financing includes 3,870,500 shares and up to 675,000 pre-funded warrants, creating substantial potential dilution.
- Units were priced at $5.50, with immediately exercisable warrants carrying a $7.50 strike price.
- The broader biotechnology sector is rising, making the company-specific financing catalyst the primary explanation for the decline.